Gapping down
In reaction to disappointing earnings/guidance: CALM -4.2%
M&A news:
In reaction to disappointing earnings/guidance: CALM -4.2%
M&A news:
- BATS -2.8% (to be acquired by CBOE for $32.50 per share, confirming media reports out last week), CBOE -2.5%
- PFE -1.2% (announces they will not pursue splitting Pfizer Innovative Health & Pfizer Essential Health into two, separate publicly traded companies)
Select financial related names showing weakness: BBVA -2.6%, RBS -2.3%, PUK -2%, SAN -1.8%, BCS -1.7%, CS -1.5%,IBN -1.3%, ING -1.1%, HSBC -0.8%
Other news:
Other news:
- PTIE -64.5% (receives a CRL from the FDA on the resubmission of its NDA for REMOXY ER)
- DRRX -33.5% (announces its licensee Pain Therapeutics (PTIE) receives complete response letter from FDA for Remoxy ER extended-release capsules CII)
- DB -5.2% (Angela Merkel ruled out public assistance over the weekend)
- ACOR -4.7% (receives confirmation from Tribunal for redemption right regarding the shares in Biotie Therapies)
- SWHC -2.5% (proposal was not selected by the Department of the Army for M9 standard Army sidearm replacement)
- MOMO -1.5% (Shanghai down ~2% overnight)
Analyst comments:
- IHG -4.5% (downgraded to Underweight from Equal Weight at Morgan Stanley)
- LYG -3.1% (downgraded to Sell from Neutral at Goldman)
- TWTR -3% (downgraded to Underperform from Perform at Oppenheimer)
- NTAP -2.4% (downgraded to Sell from Hold at Deutsche Bank)
- FINL -2.2% (downgraded to Neutral from Buy at Buckingham Research)
- LMCA -1.6% (downgraded to Hold at Wunderlich)
- DIS -0.8% (downgraded to Hold from Buy at Drexel Hamilton)
- NKE -0.6% (removed from Focus List at JP Morgan)